GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » Net Issuance of Debt

Ascentage Pharma Group International (HKSE:06855) Net Issuance of Debt : HK$-156 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Ascentage Pharma Group International's net issuance of debt for the six months ended in Dec. 2024 was HK$-50 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-156 Mil.

Ascentage Pharma Group International Net Issuance of Debt Historical Data

The historical data trend for Ascentage Pharma Group International's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Net Issuance of Debt Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Debt
Get a 7-Day Free Trial Premium Member Only 503.97 660.59 777.09 -14.61 -155.18

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 255.37 32.41 -47.02 -106.42 -49.63

Ascentage Pharma Group International Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-156 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascentage Pharma Group International Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » Net Issuance of Debt
Comparable Companies
HKSE:09606 HKSE:09969 HKSE:02696 HKSE:01952 HKSE:02162 HKSE:01548 HKSE:06826 HKSE:02410 HKSE:00775 HKSE:02171 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
AAPG:USA 36X:Germany
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Website
https://www.ascentagepharma.com
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Takeda Pharmaceuticals International Ag 2101 Beneficial owner
Takeda Pharmaceuticals Company Limited 2201 Interest of corporation controlled by you
Gao Sharon Xia
Zhai Yifan
Yang Dajun
Wang Shaomeng
Li Ju-yun
Healthquest Pharma Limited
Guo Edward Ming
Ascentage Limited
South Dakota Trust Company Llc 2301 Trustee
Tian Yuan 2201 Interest of corporation controlled by you
Zhao Li 2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you

Ascentage Pharma Group International Headlines

No Headlines